Proton-Pump Inhibitor Products Liability Litigation (No. II)
The causation theory linking PPIs to kidney injuries is supported by multiple peer-reviewed studies, FDA warnings, and expert reports. Epidemiological data demonstrate increased risks of AIN, AKI, and CKD with prolonged PPI use. The mechanisms are under investigation but likely involve drug-induced renal inflammation and damage. Regulatory agencies and legal experts recognize these risks, emphasizing cautious PPI use and kidney function monitoring.
11,321
Pending actions
18,706
Total actions filed
Active
Status
08/02/2017
Established
Filing deadline
No specific new filing deadlines or statutes of limitations are detailed in recent court orders. The court emphasizes adherence to existing statutes, with provisions for tolling during certain periods, notably tolling cases selected for the tolling list as of July 31, 2018, which are tolled as of April 16, 2018. Pending deadlines are stayed until further court order, requiring monitoring of court updates.
Who qualifies
Plaintiffs must have used PPIs regularly over a period sufficient to cause kidney injury, with diagnosis occurring within a timeframe that links the injury to PPI use. Specific durations or dosages are not explicitly detailed in court orders but generally involve prolonged, consistent use over months or years, with injury confirmed by medical diagnosis.
Products involved
- Prilosec (omeprazole)
- Nexium (esomeprazole)
- Prevacid (lansoprazole)
Alleged injuries
- Acute Interstitial Nephritis (AIN)
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
Bellwether trials
The first bellwether trial was scheduled for October 12, 2022. Subsequent court orders indicate ongoing case management and scheduled trials, with no specific upcoming trial dates explicitly listed beyond 2022. No recent verdicts or outcomes are publicly documented since October 2022.
Settlement landscape
A landmark $425 million settlement was reached with AstraZeneca in October 2023. Individual case values vary, with estimates ranging from $20,000 to over $50,000 depending on injury severity. Over 11,975 cases have been resolved since January 2025, indicating active settlement and dismissal processes. No comprehensive settlement fund or average case value has been publicly disclosed beyond the AstraZeneca settlement.
Lead counsel
- Christopher A. Seeger of Seeger Weiss, LLP
- Stephanie O’Connor of Douglas & London, P.C.
- Daniel R. Lapinsky of Wilentz, Goldman & Spitz, P.A.
- Shannon Pennock of Pennock Law Firm
- Bradley D. Honnold of Goza & Honnold, LLC
- Sindhu Daniel of Baron & Budd, PC.
- K. Camp Bailey of Bailey Peavy Bailey, PLLC
- Shayna E. Sacks of Napoli Shkolnik, PLLC
- Daniel N. Gallucci of Nastlaw, LLC
- Norman Siegel of Stueve Siegel Hanson LLP
- Derriel McCorvey of McCorvey Law, LLC
- Buffy K. Martines of Lamkin, Pirtle & Martines, LLP
- Jennie Anderson of Andrus Anderson, LLP
- Joseph Zonies of Zonies Law LLC
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
